Imdelltra tarlatamab-dlle

Drug Class

Bispecific DLL3-directed T-cell engager

Mechanism

Binds to DLL3 on tumor cells and CD3 on T cells, redirecting T cells to engage and eliminate SCLC cells.

Approved Indication

Extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, per its FDA approval.

What This Means For Patients

Imdelltra is an immunotherapy for patients with extensive-stage small cell lung cancer that has progressed despite chemotherapy. It targets a protein called DLL3 to guide the patient's immune system to attack cancer cells and is available via Boao Lecheng's import channel.

Regulatory Approvals

• FDA — approved (2024) — label

Pivotal Clinical Evidence

• DeLLphi-301 — Ahn et al., N Engl J Med 2023 (NCT05060016) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761357s000lbl.pdf